Deialdiak
16/12/2024
EP PerMed JTC 2025: Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)
16/12/2024
18/02/2025
European Commission
Proiektuak
Nazioartekoa
16/12/2024
Añadir al calendario
2024-12-16 01:00:00
2025-02-18 01:00:00
EP PerMed JTC 2025: Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)
The European Partnership for Personalised Medicine, EP PerMed, has launched its second joint transna-tional call (JTC2025) for proposals on “Pharmacogenomic strategies for personalised medicine ap-proaches”. The aim of this call is to fund research projects in human health on pharmacogenomic strategies for PM approaches that address one or more of the following aspects:
identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
More info through this link.
Location
Navarrabiomed
info@navarrabiomed
Europe/Madrid
public
The European Partnership for Personalised Medicine, EP PerMed, has launched its second joint transna-tional call (JTC2025) for proposals on “Pharmacogenomic strategies for personalised medicine ap-proaches”. The aim of this call is to fund research projects in human health on pharmacogenomic strategies for PM approaches that address one or more of the following aspects:
- identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
- validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
- use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
More info through this link.
All researchers belonging to an eligible entity from the eligible countries. Consortia will be composed of a minimum of 3 different institutions from 3 different countries and a maximum of 6 different institutions.
Through the online platform.
3 years
Depending on the funding agency